Skip to main content
. Author manuscript; available in PMC: 2019 Dec 6.
Published in final edited form as: Cell Rep. 2019 Nov 12;29(7):1848–1861.e6. doi: 10.1016/j.celrep.2019.10.012

Figure 6. Silencing the IL-23R-STAT3 Axis Rescues the Blimp1-Deficient TFr Phenotype.

Figure 6.

(A) Schematic presentation of experimental protocol. KO Treg cells were sorted and cultured withanti-CD3andanti-CD28 plusIL-2for3days. Cells were infected with lentivirus expressing the Thy1.1 reporter plus IL-23R-shRNA or Ctrl-shRNA. On day 4, sorted Thy1.1+ Treg along with CD45.1+ naive CD4+ T cells were transferred into Tcra/ hosts followed by immunization with NP-OVA in CFA on day 11. Splenocytes were analyzed on day 20.

(B) Thy1.1+ TFR, CD45.2 Thy1.1 TFH and GL7+ B cells, IL-17A, and IFNγ production by Thy1.1+ TFR.

(C) Frequency of CD45.2 Thy1.1 TFH, Bcl6+ IL-17A+, and Bcl6+ IFNγ+ in donor Thy1.1+ TFR cells and in anti-NP IgG titers.

(D–F) WT, KO, Stat3fl/+Prdm1fl/flFoxP3Cre (Stat3fl/+ + KO), and Stat3fl/flPrdm1fl/flFoxP3Cre (Stat3fl/fl + KO) mice were analyzed 10 days post-immunization with NP-OVA in CFA.

(D) Splenic TFR, TFH, GC B cells, and Bcl6+IL-17A+ in Treg.

(E) Frequency of TFR and Bcl6+IL-17A+ in Treg and in serum anti-NP IgG titers.

(F) FoxP3 expression in TFR by the indicated mouse strains.

In (A)–(C), the data represent one of two experiments (C: n = 4/group). In (D)–(F), the results are pooled from two independent experiments (E, n = 4–9/group). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 (unpaired two-tailed Student’s t test). Error bars indicate means ± SEMs.

See also Figure S5.